Eli Lilly & Co. Stock Underperforms Thursday When Compared To Competitors

Dow Jones

2025.12.04 21:31

I'm PortAI, I can summarize articles.

Eli Lilly & Co. (LLY) shares fell 1.85% to $1,014.49 on Thursday, marking the sixth consecutive day of losses. The stock underperformed compared to competitors like Johnson & Johnson, Pfizer, and AbbVie. It closed 8.77% below its 52-week high. Trading volume was slightly below the 50-day average. The S&P 500 rose 0.11%, while the Dow Jones fell 0.07%.

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Eli Lilly & Co. (LLY) shed 1.85% to $1,014.49 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index rising 0.11% to 6,857.12 and the Dow Jones Industrial Average falling 0.07% to 47,850.94. This was the stock's sixth consecutive day of losses. Eli Lilly & Co. closed 8.77% short of its 52-week high of $1,111.99, which the company achieved on November 26th. The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson (JNJ) fell 1.39% to $202.48, Pfizer Inc. (PFE) rose 0.51% to $25.70, and AbbVie Inc. (ABBV) fell 0.66% to $228.71. Trading volume (3.8 M) remained 89,325 below its 50-day average volume of 3.9 M. Data source: Dow Jones Market Data, FactSet. Data compiled December 4, 2025. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 12-04-25 1631ET